

# **Pharmaceutical Third-Party Logistics Market Size, Share & Trends Analysis Report By Product (Branded, Generic, Biosimilar), By Temperature (Ambient, Refrigerated), By Therapeutic Area, By Manufacturer Size, By Service, By Region, And Segment Forecasts, 2025 - 2030**

<https://marketpublishers.com/r/P773195413DBEN.html>

Date: January 2025

Pages: 150

Price: US\$ 5,950.00 (Single User License)

ID: P773195413DBEN

## **Abstracts**

This report can be delivered to the clients within 2 Business Days

### **Pharmaceutical Third-Party Logistics Market Growth & Trends**

The global pharmaceutical third-party logistics market is expected to reach USD 228.54 billion by 2030, expanding at a CAGR of 8.95% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven due to stringent regulatory landscapes, and the emergence of novel therapies like biologics and gene therapies which have increased the challenges associated with drug distribution. This complexity requires specialized logistics expertise that many pharmaceutical companies lack internally, encouraging them to outsource logistics functions. 3PL providers concentrate on their core competencies, such as research and development.

Furthermore, growing demand for temperature-controlled logistics is one of the factors driving market growth. Several pharmaceutical products, particularly biologics and vaccines, demand temperature control throughout the entire supply chain, from manufacturing to the point of delivery. Thus, to ensure the integrity and efficacy of these temperature-sensitive products necessitates specialized cold chain capabilities. These factors are further driving the demand for 3PL providers with the expertise and

infrastructure to maintain the required temperature conditions throughout the entire distribution process.

In addition, technological advancements are also transforming the pharmaceutical logistics landscape. The integration of cutting-edge technologies such as blockchain, the Internet of Things (IoT), and artificial intelligence (AI) is revolutionizing supply chain visibility, enhancing inventory management, and enabling real-time tracking and monitoring of shipments. These technological innovations empower 3PL providers to optimize logistics operations, minimize risks, and ensure timely and efficient delivery of pharmaceuticals to patients.

Key players in the pharmaceutical 3PL market are strategically investing in expanding their global presence, enhancing their cold chain capabilities, and integrating advanced technologies to maintain a competitive edge and meet the evolving demands of the pharmaceutical industry. The increasing complexity of global pharmaceutical supply chains and the rise in the transportation of temperature-sensitive products, have prompted 3PL providers to strengthen their cold chain logistics infrastructure. These investments focus on establishing state-of-the-art facilities, such as temperature-controlled warehouses and refrigerated transport, to ensure the safe and effective delivery of sensitive drugs. For instance, in February 2024, DHL supply chain announced to invest USD 200 million which aims to expand life sciences and healthcare logistics operations. This investment will enhance DHL's capabilities in handling temperature-sensitive pharmaceutical products, improving cold chain logistics and compliance.

## Pharmaceutical Third-Party Logistics Market Report Highlights

Based on Product, branded dominated the market due to advancements in drug formulations and the increasing availability of innovative therapies. Pharmaceutical companies are constantly developing targeted treatments for complex diseases which are contributing to the segment growth.

Based on the temperature, ambient held the largest market share in 2024, as a wide range of pharmaceutical products do not require temperature-controlled environments for storage and transportation.

Based on the therapeutic area, oncology held the largest market share in 2024. The market for the segment is projected

to expand due to the increasing prevalence of cancer worldwide and the growing demand for specialized treatments, including biologics and targeted therapies.

Based on the manufacturer size, large held the largest market share in 2024. This is primarily due to their extensive production capabilities, larger distribution networks, and greater financial resources to invest in advanced logistics solutions.

Based on the service, storage and shipping held the largest market share in 2024. This is due to the critical need for secure, reliable storage and efficient transportation of pharmaceutical products, including temperature-sensitive drugs.

## Contents

### CHAPTER 1. METHODOLOGY AND SCOPE

- 1.1. Market Segmentation & Scope
- 1.2. Market Definitions
  - 1.2.1. Product Segment
  - 1.2.2. Temperature Segment
  - 1.2.3. Therapeutic Area Segment
  - 1.2.4. Manufacturer Size Segment
  - 1.2.5. Service Segment
- 1.3. Information Analysis
  - 1.3.1. Market Formulation & Data Visualization
- 1.4. Data Validation & Publishing
- 1.5. Information Procurement
  - 1.5.1. Primary Research
- 1.6. Information or Data Analysis
- 1.7. Market Formulation & Validation
- 1.8. Market Model
- 1.9. Objectives

### CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot

### CHAPTER 3. MARKET VARIABLES, TRENDS, & SCOPE

- 3.1. Market Lineage Outlook
  - 3.1.1. Parent Market Outlook
  - 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Trends and Outlook
- 3.3. Market Dynamics
  - 3.3.1. Market Driver Analysis
    - 3.3.1.1. The Rise of E-Commerce
    - 3.3.1.2. Growing Demand for Outsourcing Services
    - 3.3.1.3. Rising Demand for Cold Chain Logistics
    - 3.3.1.4. Growing Applications of Reverse Logistics in Biopharmaceutical Industry

- 3.3.2. Market Restraint Analysis
  - 3.3.2.1. High Operational Costs
  - 3.3.2.2. Compliance Issues While Outsourcing
- 3.4. Industry Analysis Tools
  - 3.4.1. Porter's Five Forces Analysis
  - 3.4.2. PESTEL Analysis
  - 3.4.3. COVID-19 Impact Analysis

## **CHAPTER 4. PHARMACEUTICAL THIRD-PARTY LOGISTICS (3PL) SERVICES MARKET: PRODUCT ESTIMATES & TREND ANALYSIS**

- 4.1. Segment Dashboard
- 4.2. Pharmaceutical Third-Party Logistics (3PL) Services Market; Product Movement Analysis
- 4.3. Pharmaceutical Third-Party Logistics (3PL) Services Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
- 4.4. Branded
  - 4.4.1. Branded market estimates and forecasts 2018 to 2030 (USD Million)
- 4.5. Generic
  - 4.5.1. Generic market estimates and forecasts 2018 to 2030 (USD Million)
- 4.6. Biosimilar
  - 4.6.1. Biosimilar market estimates and forecasts 2018 to 2030 (USD Million)
- 4.7. Vaccine
  - 4.7.1. Vaccine market estimates and forecasts 2018 to 2030 (USD Million)
- 4.8. Cell Therapy
  - 4.8.1. Cell therapy market estimates and forecasts 2018 to 2030 (USD Million)
- 4.9. Gene Therapy
  - 4.9.1. Gene therapy market estimates and forecasts 2018 to 2030 (USD Million)
- 4.10. Others
  - 4.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

## **CHAPTER 5. PHARMACEUTICAL THIRD-PARTY LOGISTICS (3PL) SERVICES MARKET: TEMPERATURE ESTIMATES & TREND ANALYSIS**

- 5.1. Segment Dashboard
- 5.2. Pharmaceutical Third-Party Logistics (3PL) Services Market; Temperature Movement Analysis
- 5.3. Pharmaceutical Third-Party Logistics (3PL) Services Size & Trend Analysis, by Temperature, 2018 to 2030 (USD Million)

#### 5.4. Ambient

5.4.1. Ambient market estimates and forecasts 2018 to 2030 (USD Million)

#### 5.5. Refrigerated

5.5.1. Refrigerated market estimates and forecasts 2018 to 2030 (USD Million)

#### 5.6. Frozen

5.6.1. Frozen market estimates and forecasts 2018 to 2030 (USD Million)

#### 5.7. Ultra-frozen/Deep-Frozen

5.7.1. Ultra-frozen/Deep-Frozen market estimates and forecasts 2018 to 2030 (USD Million)

#### 5.8. Cryogenic

5.8.1. Cryogenic market estimates and forecasts 2018 to 2030 (USD Million)

### **CHAPTER 6. PHARMACEUTICAL THIRD-PARTY LOGISTICS (3PL) SERVICES MARKET: THERAPEUTIC AREA ESTIMATES & TREND ANALYSIS**

#### 6.1. Segment Dashboard

#### 6.2. Pharmaceutical Third-Party Logistics (3PL) Services Market; Therapeutic Area Movement Analysis

#### 6.3. Pharmaceutical Third-Party Logistics (3PL) Services Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)

#### 6.4. Oncology

6.4.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)

#### 6.5. Cardiovascular Diseases

6.5.1. Cardiovascular diseases market estimates and forecasts 2018 to 2030 (USD Million)

#### 6.6. Infectious Diseases

6.6.1. Infectious diseases market estimates and forecasts 2018 to 2030 (USD Million)

#### 6.7. Neurology

6.7.1. Neurology market estimates and forecasts 2018 to 2030 (USD Million)

#### 6.8. Diabetes

6.8.1. Diabetes market estimates and forecasts 2018 to 2030 (USD Million)

#### 6.9. Nephrology

6.9.1. Nephrology market estimates and forecasts 2018 to 2030 (USD Million)

#### 6.10. Rheumatology

6.10.1. Rheumatology market estimates and forecasts 2018 to 2030 (USD Million)

#### 6.11. Allergy/Asthma

6.11.1. Allergy/Asthma market estimates and forecasts 2018 to 2030 (USD Million)

#### 6.12. Gastroenterology

6.12.1. Gastroenterology market estimates and forecasts 2018 to 2030 (USD Million)

#### 6.13. Ophthalmology

6.13.1. Ophthalmology market estimates and forecasts 2018 to 2030 (USD Million)

#### 6.14. Others

6.14.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

### **CHAPTER 7. PHARMACEUTICAL THIRD-PARTY LOGISTICS (3PL) SERVICES MARKET: MANUFACTURER SIZE ESTIMATES & TREND ANALYSIS**

#### 7.1. Segment Dashboard

7.2. Pharmaceutical Third-Party Logistics (3PL) Services Market; Manufacturer Size Movement Analysis

7.3. Pharmaceutical Third-Party Logistics (3PL) Services Size & Trend Analysis, by Manufacturer Size, 2018 to 2030 (USD Million)

#### 7.4. Large

7.4.1. Large market estimates and forecasts 2018 to 2030 (USD Million)

#### 7.5. Medium

7.5.1. Medium market estimates and forecasts 2018 to 2030 (USD Million)

#### 7.6. Small

7.6.1. Small market estimates and forecasts 2018 to 2030 (USD Million)

### **CHAPTER 8. PHARMACEUTICAL THIRD-PARTY LOGISTICS (3PL) SERVICES MARKET: SERVICE ESTIMATES & TREND ANALYSIS**

#### 8.1. Segment Dashboard

8.2. Pharmaceutical Third-Party Logistics (3PL) Services Market; Service Movement Analysis

8.3. Pharmaceutical Third-Party Logistics (3PL) Services Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)

#### 8.4. Storage and Shipping

8.4.1. Storage and Shipping market estimates and forecasts 2018 to 2030 (USD Million)

#### 8.5. Order-to-cash

8.5.1. Order-to-cash market estimates and forecasts 2018 to 2030 (USD Million)

#### 8.6. Title Model

8.6.1. Title Model market estimates and forecasts 2018 to 2030 (USD Million)

#### 8.7. DSCSA and Serialization Services

8.7.1. DSCSA and Serialization Services market estimates and forecasts 2018 to 2030 (USD Million)

#### 8.8. Pharmaceutical Sampling



8.8.1. Pharmaceutical Sampling market estimates and forecasts 2018 to 2030 (USD Million)

8.9. Others

8.9.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

## **CHAPTER 9. REGIONAL BUSINESS ANALYSIS**

9.1. Regional Dashboard

9.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030

9.3. North America

9.3.1. North America Pharmaceutical Third-party Logistics Market, 2018 - 2030 (USD Million)

9.3.2. U.S.

9.3.2.1. Key Country Dynamics

9.3.2.2. Competitive Scenario

9.3.2.3. Regulatory Framework

9.3.2.4. U.S. Pharmaceutical Third-party Logistics Market, 2018 - 2030 (USD Million)

9.3.3. Canada

9.3.3.1. Key Country Dynamics

9.3.3.2. Competitive Scenario

9.3.3.3. Regulatory Framework

9.3.3.4. Canada Pharmaceutical Third-party Logistics Market, 2018 - 2030 (USD Million)

9.3.4. Mexico

9.3.4.1. Key Country Dynamics

9.3.4.2. Competitive Scenario

9.3.4.3. Regulatory Framework

9.3.4.4. Mexico Pharmaceutical Third-party Logistics Market, 2018 - 2030 (USD Million)

9.4. Europe

9.4.1. Europe Pharmaceutical Third-party Logistics Market, 2018 - 2030 (USD Million)

9.4.2. Germany

9.4.2.1. Key Country Dynamics

9.4.2.2. Competitive Scenario

9.4.2.3. Regulatory Framework

9.4.2.4. Germany Pharmaceutical Third-party Logistics Market, 2018 - 2030 (USD Million)

9.4.3. UK

9.4.3.1. Key Country Dynamics



9.4.3.2. Competitive Scenario

9.4.3.3. Regulatory Framework

9.4.3.4. UK Pharmaceutical Third-party Logistics Market, 2018 - 2030 (USD Million)

9.4.4. France

9.4.4.1. Key Country Dynamics

9.4.4.2. Competitive Scenario

9.4.4.3. Regulatory Framework

9.4.4.4. France Pharmaceutical Third-party Logistics Market, 2018 - 2030 (USD Million)

9.4.5. Italy

9.4.5.1. Key Country Dynamics

9.4.5.2. Competitive Scenario

9.4.5.3. Regulatory Framework

9.4.5.4. Italy Pharmaceutical Third-party Logistics Market, 2018 - 2030 (USD Million)

9.4.6. Spain

9.4.6.1. Key Country Dynamics

9.4.6.2. Competitive Scenario

9.4.6.3. Regulatory Framework

9.4.6.4. Spain Pharmaceutical Third-party Logistics Market, 2018 - 2030 (USD Million)

9.4.7. Denmark

9.4.7.1. Key Country Dynamics

9.4.7.2. Competitive Scenario

9.4.7.3. Regulatory Framework

9.4.7.4. Denmark Pharmaceutical Third-party Logistics Market, 2018 - 2030 (USD Million)

9.4.8. Sweden

9.4.8.1. Key Country Dynamics

9.4.8.2. Competitive Scenario

9.4.8.3. Regulatory Framework

9.4.8.4. Sweden Pharmaceutical Third-party Logistics Market, 2018 - 2030 (USD Million)

9.4.9. Norway

9.4.9.1. Key Country Dynamics

9.4.9.2. Competitive Scenario

9.4.9.3. Regulatory Framework

9.4.9.4. Norway Pharmaceutical Third-party Logistics Market, 2018 - 2030 (USD Million)

9.5. Asia Pacific

9.5.1. Asia Pacific Pharmaceutical Third-party Logistics Market, 2018 - 2030 (USD Million)

9.5.2. Japan

9.5.2.1. Key Country Dynamics

9.5.2.2. Competitive Scenario

9.5.2.3. Regulatory Framework

9.5.2.4. Japan Pharmaceutical Third-party Logistics Market, 2018 - 2030 (USD Million)

9.5.3. China

9.5.3.1. Key Country Dynamics

9.5.3.2. Competitive Scenario

9.5.3.3. Regulatory Framework

9.5.3.4. China Pharmaceutical Third-party Logistics Market, 2018 - 2030 (USD Million)

9.5.4. India

9.5.4.1. Key Country Dynamics

9.5.4.2. Competitive Scenario

9.5.4.3. Regulatory Framework

9.5.4.4. India Pharmaceutical Third-party Logistics Market, 2018 - 2030 (USD Million)

9.5.5. South Korea

9.5.5.1. Key Country Dynamics

9.5.5.2. Competitive Scenario

9.5.5.3. Regulatory Framework

9.5.5.4. South Korea Pharmaceutical Third-party Logistics Market, 2018 - 2030 (USD Million)

9.5.6. Australia

9.5.6.1. Key Country Dynamics

9.5.6.2. Competitive Scenario

9.5.6.3. Regulatory Framework

9.5.6.4. Australia Pharmaceutical Third-party Logistics Market, 2018 - 2030 (USD Million)

9.5.7. Thailand

9.5.7.1. Key Country Dynamics

9.5.7.2. Competitive Scenario

9.5.7.3. Regulatory Framework

9.5.7.4. Thailand Pharmaceutical Third-party Logistics Market, 2018 - 2030 (USD Million)

9.6. Latin America

9.6.1. Latin America Pharmaceutical Third-party Logistics Market, 2018 - 2030 (USD

Million)

9.6.2. Brazil

9.6.2.1. Key Country Dynamics

9.6.2.2. Competitive Scenario

9.6.2.3. Regulatory Framework

9.6.2.4. Brazil Pharmaceutical Third-party Logistics Market, 2018 - 2030 (USD

Million)

9.6.3. Argentina

9.6.3.1. Key Country Dynamics

9.6.3.2. Competitive Scenario

9.6.3.3. Regulatory Framework

9.6.3.4. Argentina Pharmaceutical Third-party Logistics Market, 2018 - 2030 (USD

Million)

9.7. MEA

9.7.1. MEA Pharmaceutical Third-party Logistics Market, 2018 - 2030 (USD Million)

9.7.2. South Africa

9.7.2.1. Key Country Dynamics

9.7.2.2. Competitive Scenario

9.7.2.3. Regulatory Framework

9.7.2.4. South Africa Pharmaceutical Third-party Logistics Market, 2018 - 2030 (USD

Million)

9.7.3. Saudi Arabia

9.7.3.1. Key Country Dynamics

9.7.3.2. Competitive Scenario

9.7.3.3. Regulatory Framework

9.7.3.4. Saudi Arabia Pharmaceutical Third-party Logistics Market, 2018 - 2030 (USD

Million)

9.7.4. UAE

9.7.4.1. Key Country Dynamics

9.7.4.2. Competitive Scenario

9.7.4.3. Regulatory Framework

9.7.4.4. UAE Pharmaceutical Third-party Logistics Market, 2018 - 2030 (USD Million)

9.7.5. Kuwait

9.7.5.1. Key Country Dynamics

9.7.5.2. Competitive Scenario

9.7.5.3. Regulatory Framework

9.7.5.4. Kuwait Pharmaceutical Third-party Logistics Market, 2018 - 2030 (USD

Million)

## CHAPTER 10. COMPETITIVE LANDSCAPE

- 10.1. Company Categorization
- 10.2. Company Market Position Analysis, 2024
- 10.3. Company Profiles
  - 10.3.1. CEVA Logistics
    - 10.3.1.1. Company overview
    - 10.3.1.2. Financial performance
    - 10.3.1.3. Service benchmarking
    - 10.3.1.4. Strategic initiatives
  - 10.3.2. Cencora Corporation (ICS)
    - 10.3.2.1. Company overview
    - 10.3.2.2. Financial performance
    - 10.3.2.3. Service benchmarking
    - 10.3.2.4. Strategic initiatives
  - 10.3.3. DB SCHENKER
    - 10.3.3.1. Company overview
    - 10.3.3.2. Financial performance
    - 10.3.3.3. Service benchmarking
    - 10.3.3.4. Strategic initiatives
  - 10.3.4. Kuehne+Nagel
    - 10.3.4.1. Company overview
    - 10.3.4.2. Financial performance
    - 10.3.4.3. Service benchmarking
    - 10.3.4.4. Strategic initiatives
  - 10.3.5. Kerry Logistics Network Limited
    - 10.3.5.1. Company overview
    - 10.3.5.2. Financial performance
    - 10.3.5.3. Service benchmarking
    - 10.3.5.4. Strategic initiatives
  - 10.3.6. Cardinal Health
    - 10.3.6.1. Company overview
    - 10.3.6.2. Financial performance
    - 10.3.6.3. Service benchmarking
    - 10.3.6.4. Strategic initiatives
  - 10.3.7. McKesson Corporation
    - 10.3.7.1. Company overview
    - 10.3.7.2. Financial performance
    - 10.3.7.3. Service benchmarking

10.3.7.4. Strategic initiatives

10.3.8. EVERSANA.

10.3.8.1. Company overview

10.3.8.2. Financial performance

10.3.8.3. Service benchmarking

10.3.8.4. Strategic initiatives

10.3.9. Thermo Fisher Scientific Inc.

10.3.9.1. Company overview

10.3.9.2. Financial performance

10.3.9.3. Service benchmarking

10.3.9.4. Strategic initiatives

10.3.10. Knipper Health

10.3.10.1. Company overview

10.3.10.2. Financial performance

10.3.10.3. Service benchmarking

10.3.10.4. Strategic initiatives

## I would like to order

Product name: Pharmaceutical Third-Party Logistics Market Size, Share & Trends Analysis Report By Product (Branded, Generic, Biosimilar), By Temperature (Ambient, Refrigerated), By Therapeutic Area, By Manufacturer Size, By Service, By Region, And Segment Forecasts, 2025 - 2030

Product link: <https://marketpublishers.com/r/P773195413DBEN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P773195413DBEN.html>